priors.science/reviews/predictive-biomarkers-immunotherapy

Predictive Biomarkers Immunotherapy

The current evidence on 19 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

19claims tracked
188primary papers reviewed
2 Jun 2026latest evidence review
Weeklyre-scored against new papers
5 Established · 9 Likely · 5 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableMicrosatellite instability-high is the best immune checkpoint inhibitor biomarkerMsi HEstablished93%10
StableMismatch repair-deficient endometrial immune checkpoint inhibitor responseMsi HEstablished92%10
StablePD-L1 assays are non-interchangeablePdl1Established91%10
StablePD-L1 tumour proportion score predictor in non-small-cell lung cancerPdl1Established90%10
StableMicrosatellite instability-high versus microsatellite-stable immune checkpoint inhibitor selectivityMsi HEstablished89%10
StableBiomarker prediction across cancer typesMulti BiomarkerLikely77%10
StableCirculating tumour DNA clearance on-treatment with immune checkpoint inhibitorsCtdnaLikely75%10
StablePD-L1 combined positive score predictor in gastro-oesophageal adenocarcinomaPdl1Likely74%8
StableCold tumours and immune checkpoint inhibitor resistanceTilLikely74%10
StableTumour-infiltrating lymphocyte density predicts immune checkpoint inhibitor responseTilLikely73%10
StableMulti-biomarker prediction superiorityMulti BiomarkerLikely71%10
StableInterferon-gamma gene signature predicts immune checkpoint inhibitor responseIfngLikely70%10
StableTumour mutational burden cutoff is cancer-type specificTMBLikely70%10
StableNeoantigen burden and immune checkpoint inhibitor responseNeoantigenLikely68%10
StablePre-treatment circulating tumour DNA for immune checkpoint inhibitor selectionCtdnaUncertain58%10
StableBlood versus tissue tumour mutational burden discordanceTMBUncertain57%10
StableTumour mutational burden pan-tumour immune checkpoint inhibitor FDA approvalTMBUncertain54%10
StableHuman leukocyte antigen heterozygosity and immune checkpoint inhibitor durabilityNeoantigenUncertain52%10
StableJAK/STAT interferon pathway and immune checkpoint inhibitor resistanceIfngUncertain51%10
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic